No Data
No Data
Express News | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Olema Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29
Capital One Financial Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $26
Promising Potential of Olema Pharmaceuticals' Palazestrant and KAT6 Inhibitor Fuels Buy Rating
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
No Data
No Data